Elicio Therapeutics (ELTX) Interest Expenses (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Interest Expenses came in at $11.6 million in Q1 2026, up 3358.68% YoY from $334000.0 in Q1 2025, and up 3317.75% on a QoQ basis from $338000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Interest Expenses (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Interest Expenses data on file, last reported at $11.6 million in Q1 2026.
- Quarterly Interest Expenses rose 3358.68% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 5427.27% YoY) and the FY2025 annual result came in at $5.1 million, down 94.95% from the prior year.
- Interest Expenses improved to $11.6 million in Q1 2026, from $338000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $11.6 million in Q1 2026 to a low of -$641000.0 in Q4 2024.
- A 5-year average of $3.3 million and a median of $379000.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses tumbled 269.58% — and 2025, when it surged 7582.48%.
- Tracing ELTX's Interest Expenses over 5 years: stood at $92000.0 in 2022, then jumped by 310.87% to $378000.0 in 2023, then plunged by 269.58% to -$641000.0 in 2024, then soared by 152.73% to $338000.0 in 2025, then surged by 3317.75% to $11.6 million in 2026.
- The last three Interest Expenses figures came in at $11.6 million (Q1 2026), $338000.0 (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 410,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.35 Mn |
| Jun 30, 2026 | 5.35 Mn |
| Mar 31, 2026 | 11.55 Mn |
| Mar 31, 2026 | 11.55 Mn |
| Dec 31, 2025 | 338,000.00 |
| Dec 31, 2025 | 338,000.00 |
| Sep 30, 2025 | 10.53 Mn |
| Sep 30, 2025 | 10.53 Mn |
| Jun 30, 2025 | 6.72 Mn |
| Jun 30, 2025 | 6.72 Mn |
| Mar 31, 2025 | 334,000.00 |
| Mar 31, 2025 | 334,000.00 |
| Dec 31, 2024 | -641,000.00 |
| Dec 31, 2024 | -641,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 8.05 Mn |
| Jun 30, 2024 | 8.05 Mn |
| Mar 31, 2024 | 379,000.00 |
| Mar 31, 2024 | 379,000.00 |